Previous close | 5.55 |
Open | 5.55 |
Bid | 0.00 x 1200 |
Ask | 0.00 x 1800 |
Day's range | 5.31 - 5.64 |
52-week range | 4.56 - 39.41 |
Volume | |
Avg. volume | 1,716,325 |
Market cap | 248.598M |
Beta (5Y monthly) | 1.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.45 |
Earnings date | 22 Feb 2022 - 28 Feb 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 26.09 |
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
VANCOUVER, British Columbia, May 04, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2022.
VANCOUVER, British Columbia & SEATTLE, May 02, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: